medigraphic.com

2000, Number 3

<< Back Next >>

Rev Med Hosp Gen Mex 2000; 63 (3)

Thalidomide: Another chance

Fernández-Camacho Y, Leon-Dorantes G

Language: Spanish
References: 82
Page: 185-191
PDF size: 148.46 Kb.


ABSTRACT

Thalidomide, originally marketed as a sedative drug, was introduced in Eastern Germany in 1956 and in numerous other countries thereafter. It became extremely popular very rapidly because it did not impair coordination or respiratory function. By 1961, however, there were mounting reports of phocomelia and other severe congenital abnormalities associated with maternal use of thalidomide, and the drug was withdrawn from the market and its availability highly restricted. Nevertheless, when used in two leprosy patients with erythema nodosum leprosum (ENL) that experienced rapid and dramatic improvement taking the drug it became the drug of choice in this condition. In subsequent decades, it was used in multiple dermatologic and non-dermatologic diseases, as it has been discovery various biologic effects mainly immunomodulatory such as inhibition of tumor necrosis factor alpha (FNT-a). Main pharmacologic issues and new mechanisms of action as well as reports upon its use in diseases such as lupus erythematosus, Behçet’s disease, actinic prurigo, aphtous stomatitis, prurigo nodularis, graft versus host disease (GVHD) and human immunodeficiency virus infection (HIV), are discussed.


REFERENCES

  1. . Rivitti E, Talidomida en Dermatología. Med Cutan Iber Lat Am 1997; 25: 117-129.

  2. Vázquez H, Arenas R, Talidomida en Dermatología: Revisión de sus orígenes, su actual redescubrimiento y nuevas aplicaciones. Rev Mex Dermatol 1998; 42: 252-265.

  3. Barnhill R, McDougall C, Thalidomide: Use and possible mode of action in reactional lepromatous leprosy and in various other conditions. J Am Acad Dermatol 1982; 7: 317-323.

  4. Londoño F. Thalidomide in the treatment of actinic prurigo. Int J Dermatol 1973; 12: 326-328.

  5. Flores O. Prúrigo solar de altiplanicie. Resultados preliminares de tratamiento con talidomida en 25 casos. Rev Mex Dermatol 1975; 19: 26-39.

  6. Barba-Rubio, Franco-González. Lupus eritematoso discoide. Informe preliminar. Rev Mex Dermatol 1972; 21: 131-139.

  7. Tseng S, Pak G, Washenik K, Keltz M, Shupack J. Reediscovering thalidomide: A review of its mechanism of action, side effects, and potential uses. J Am Acad Dermatol 1996; 35: 969-979.

  8. Grinspan D. Significant response of oral aphtosis thalidomide treatment. J Am Acad Dermatol 1985; 12: 85-90.

  9. Saylan T, Saltik I. Thalidomide in the treatment of Behçet syndrome. Arch Dermatol 1982; 118: 536.

  10. Jorizzo J, Schmalstieg F, Solomon A, et al. Thalidomide effects in Behçet’s syndrome and pustular vasculitis. Arch Int Med 1986; 146: 876-881.

  11. Lim S, Mc Whannell, Vora A, Boughtton B. Successful Treatment with thalidomide of acute graft-versus-host-disease after bone-marrow transplantation. Lancet 1988; 16: 117.

  12. Beunier L, Marck Y, Ribeyre C. Adult cutaneous Langerhans cell histiocytosis: Remission with thalidomide treatment. Br J Dermatol 1995; 132: 168.

  13. Corral LG, Haslett PA, Muller GW, et al. Differential cytokine modulation and T cell activation by two distinct classes of thalidomide analogues that are potent inhibitors of FNT-a. J Inmunol 1999; 163 (1): 380-386.

  14. Sampaio E, Kaplan G, Miranda A, Nery J, Miguel C, Viana S, Sarno E. The influence of thalidomide on the clinical and immunologic and manifestation erythema nodosum leprosum. J Infect Dis 1993; 168: 408-414.

  15. Stirling D. Thalidomide and its impact in dermatology. Sem Cutan Med Surg 1998; 14: 231-242.

  16. Sheldon S, Hendler F, Mark F. Thalidomide for autoimmune disease. Med Hypothesis 1983; 10: 437-43.

  17. Haslett P. Anticytokine approaches to the treatment of anorexia and cachexia. Semin Oncol 1985; 25 (suppl 6): 53-57.

  18. Rebuck J, Pharm D, Fish DN. Thalidomide Revisited. AIDS Reader 1998; 8: 7-9.

  19. Fine HA, Figg WD, Jaeckle K, et al. Phase II trial of the antiangiogenic agent thalidomide in patients with recurrent high-grade gliomas. Clin Oncol 2000; 18: 708.

  20. Soler RA, Howard M, Brink NS, Gibb D, Tedder RS, Nadal D. Regression of AIDS-related Kaposi’s sarcoma during therapy with thalidomide. Clin Infect Dis 1996; 23: 501-503.

  21. Calderon P, Azilotti M, Phelps R. Thalidomide in Dermatology. New indications for an old drug. Int J Dermatol 1997; 36: 881-887.

  22. Sheskin J. The treatment of lepra reaction in lepromatous leprosy. Fifteen years’ experience with thalidomide. Int J Dermatol 1980; 6: 318-322.

  23. Saúl A. Thalidomidedependence and thalidomideresistence. Leprología 1974; 19: 2.

  24. Epstein JH. Tratamiento del prúrigo actínico. Rev Mex Dermatol 1993; 37 (suppl 1): 335-336.

  25. Lovell C, Hawk J, Calnan C, Magnus I. Thalidomide in actinic prurigo. Br J Dermatol 1983; 108: 467-471.

  26. Flores O. Prúrigo solar de altiplanicie: Tratamiento con talidomida. Rev Mex Dermatol 1993; 37 (Suppl 1): 337-338.

  27. Vega ME, Hojyo MT, Domínguez L. Tratamiento del prúrigo actínico con talidomida. Estudio en 30 pacientes. Rev Mex Dermatol 1993; 37(Suppl 1): 342-343.

  28. Hasper MF. Chronic cutaneous lupus erythematosus. thalidomide treatment of 11 patients. Arch Dermatol 1983; 119: 812-815.

  29. Hallman S. Chronic cutaneous lupus erythematosus. Arch Dermatol 1993; 119: 812-815.

  30. Burrows N, Walport M, Hammond A, Davey N, Russell J. Lupus erythematosus profundus with partial C4 deficiency responding to thalidomide. Br J Dermatol 1991; 125: 62-67.

  31. Bessis D, Guillot B, Mondpoint S, Dandurand M, Guilhou JJ. Thalidomide for Systemic Lupus Erythematosus. Lancet 1992; 339: 29: 549-550.

  32. Ship JA, Arbor A. Recurrent aphtous stomatitis. An update. Oral Surg Oral Med Oral Pathol Oral Radio Endod 1996; 81: 141-147.

  33. Torras H, Lecha M, Mascaro J. Thalidomide treatment of recurrent necrotic giant mucocutaneous aphtae and aphtosis. Arch Dermatol 1992; 18: 875.

  34. Revuz J, Guillaume JC, Janier M et al. Crossover study of thalidomide vs placebo in severe recurrent aphtous stomatitis. Arch Dermatol 1990; 126: 923-927.

  35. Jorizzo J, Jayashri G. Behçet’s disease and complex aphtosis. J Am Acad Dermatol 1999; 40(1): 1-20.

  36. Larsson H. Treatment of severe colitis in Behçet’s syndrome with thalidomide (CG-217). J Int Med 1990; 228: 405-407.

  37. Hamuryudan V, Mat C, Saip S et al. Thalidomide in the treatment of the mucocutaneous lesions for the Behçet syndrome. A randomized, double-blind, placebo-controlled trial. Ann Intern Med 1998; 128: 443-50.

  38. Erlich GE. Behçet disease and the emergence of thalidomide. Ann Int Med 1998; 128: 494-495.

  39. Ghigliotti G, Repetto T, Farris A, Roy MT, De Marchi R. Thalidomide: Treatment of choice for aphtous ulcers in patients seropositive for human immunodeficiency virus. J Am Acad Dermatol 1993; 28: 271-272.

  40. Jacobson JM, Greenspan JS, Spritzler et al. Thalidomide for the treatment of oral aphtous ulcers in patients with human immunodeficiency virus infections. N Engl J Med 1997; 336: 1487-1493.

  41. Parker PM, Chao N, Nademanee A et al. Thalidomide as Salvage Therapy for Chronic Graft-Versus-Host Disease. Blood 1995; 86: 3604-3609.

  42. Lewis JM. Ragland E. Graft-versus-host reactions in dermatology. J Am Acad Dermatol 1998; 38: 369-396.

  43. Voegelsang G, Farmer E, Hess A et al. Thalidomide For The Treatment of Chronic Graft-Versus-Host-Disease. N Engl J Med 1992; 326: 1055-1058.

  44. Winkelmann R, Connoly S, Doyle J, Padilha-Goncalves A. Thalidomide treatment of prurigo nodularis. Acta Derm Venereol 1984; 64: 412-417.

  45. Berger TGB, Hoffman C, Thieberg M. Prurigo nodularis and photosensitivity in aids: treatment with talidomida. J Am Acad Dermatol 1995; 33: 837-838.

  46. Herranz P, Pizorro A, De Lucas R et al. Treatment of AIDS-associated prurigo nodularis with thalidomide. Clin Exp Dermatol 1998; 23: 233-235.

  47. Ferrandiz C, Carrascosa JM, Just M, Bielsa I, Ribera M. Sequential combined therapy with thalidomide and narrow-band (TL01) UVB in the treatment of prurigo nodularis. Dermatology 1997; 195: 359-361.

  48. Gnassia AM, Gnassia RT, Bonvalet D et al. Histiocytose X avec “granulome eosinophile vulvaire”: Effet spectaculaire de la thalidomide. Ann Dermatol Venereol 1987; 114: 1387-1389.

  49. Bensaid PH, Machet L, Vaillant L, Machet MC, Scotto B, Lorette G. Histiocytose langerhansienne de l’adulte: localisation parotidienne régressive aprés traitement par thalidomide. Ann Dermatol Venereol 1992; 119: 281-283.

  50. Thomas L, Ducros B, Secchi T, Balme B, Moulin G. Successful treatment of adult’s Langerhans cell histiocytosis with thalidomide. Report of two cases and literature. Review. Arch Dermatol 1993; 129: 1261-4.

  51. Moisson Y, Janier M, Civatte J. Thalidomide for recurrent erythema multiforme. Br J Dermatol 1988; 119: 92-93.

  52. Guillaume JC, Moulin G, Dieng M et al. Crossover study of thalidomide vs placebo in Jessner’s lymphocytic infiltration of the skin. Arch Dermatol 1995; 131: 1032-1035.

  53. Eravelly J, Waters. Thalidomide in Weber-Christian. Lancet 1977; 1: 251.

  54. Silva S, Viana PC, Lugon NV. Thalidomide for the treatment of uremic pruritus: A crossover randomized doble-blind trial. Nephron 1994; 67: 270-273.

  55. Dereure O, Basset-Seguin N, Guiljou. Erosive lichen planus: Dramatic response to thalidomide. Arch Dermatol 1996; 132: 96-97.

  56. Safa G, Joly P. Boullie MC, Thomine E, Lauret P. Melkersson-Rosenthal syndrome treated by thalidomide. 2 cases. Ann Dermatol Venereol 1995; 122 (9): 625-626.

  57. Hecker M, Lebwohl M. Recalcitrant pyoderma gangrenosum: Treatment with Thalidomide. J Am Acad Dermatol 1998; 38: 490-491.

  58. Carlesimo M, Giustini S, Rossi A, Bonaccorsi P, Calvieri S. Treatment of cutaneous and pulmonary sarcoidosis with thalidomide. J Am Acad Dermatol 1995; 866-868.

  59. Lee J, Koblenzer P. Disfuring cutaneous manifestation of sarcoidosis treated with thalidomide: A case report. J Am Acad Dermatol 1998; 39: 835-838.

  60. Naafs B, Faber W. Thalidomide therapy: an open trial. Int J Dermatol 1985; 24: 131-134.

  61. Benchikhi H, Bodemer C, Fraitag S et al. Treatment of cutaneous lymphoid hyperplasia with thalidomide: Report of two cases. J Am Acad Dermatol 1999; 40: 1005-1007.

  62. Walters M, Laing A, Ambikapathy A. Treatment of ulcerative colitis with thalidomide. Br Med J 1979; 1: 792.

  63. Yoshiki M. A possible mechanism of action thalidomide on rheumatoid arthritis. Arthritis Rheum 1985; 28: 836.

  64. Breban M, Gombert B, Amor B, Dougados M. Efficacy of thalidomide in the treatment of refractory ankylosing spondylitis. J Rheumatol 1994; 21: 580-581.

  65. Gori A, Franzetti F, Marchetti G et al. Clinical and immunological improvement in a patient who received thalidomide treatment for refractory Mycobacterium avium complex infection. Clin Infect Dis 1998; 26: 184-185.

  66. Arrieta O, Ortiz-Reyes A, Rembao D, Calvillo M, Rivera E, Sotelo J. Protective effect of pentoxifylline plus thalidomide against septic shock in mice. Int J Exp Pathol 1999; 80 (1): 11-6.

  67. Dixon S, Kruger E, Bauer K, Figg W. Thalidomide up-regulates prostate-specific antigen secretion from LNCaP cells. Cancer Chemother Pharmacol 1999; 43: S78-84.

  68. Singhal S Jayesh M, Desikan R et al. Antitumor activity of thalidomide in refractory multiple myeloma. N Eng J Med 1999; 341: 1565-1571.

  69. Raje N. Anderson K. Thalidomide. A revival story. N Eng J Med 1998; 341: 1806-1809.

  70. Wolkenstein P y cols. Comparison of thalidomide versus placebo in toxic epidermal necrolysis. Lancet 1998; 352(9140): 1586-1589.

  71. Lipson AH. Thalidomide Retrospective: What did the clinical teratologist learn? Teratology 1992; 46: 411-413.

  72. Brent RL. The contributions of Widukind Lenz to teratology and science: Comment on “Thalidomide retrospective: What did the clinical teratologist learn?” Teratology 1992; 46: 415-416.

  73. Stepehns TD, Fillmore BJ. Hypothesis: Thalidomide embryopathy-proposed mechanism of action. Teratology 2000; 61: 189-195.

  74. McBride WG. Thalidomide and congenital abnormalities. Lancet 1961; 16: 1358.

  75. Tappeiner G, Wolff K. Thalidomide. In: Fitzpatrick. Dermatology in general medicine. 5a ed. New York: McGraw-Hill 1999; 2864-2870.

  76. Clemmensen O, Olsen O, Andersen K. Thalidomide Neurotoxicity. Arch Dermatol 1984; 120: 338-341.

  77. Fullerton P. Neuropathy after intake thalidomide (Distaval). Br Med J 1961; 30: 855-858.

  78. Ochonisky S, Verroust J, Bastuji-Garin, Gherald R, Revuz J. Thalidomide neuropathy incidence and clinicoelectrophysiologic findings in 42 patients. Arch Dermatol 1994; 130: 66-69.

  79. Fullerton P, Sullivan D. Thalidomide neuropathy: A clinical, electrophysiological, and histological follow-up study. J Neurol Neurosurg Psychiat 1968; 31: 543-551.

  80. Bielsa I, Teixidó J, Ribera M, Ferrándiz C. Erythroderma due to thalidomide: Report of two cases. Dermatology 1994; 189: 179-181.

  81. Haslett P, Tromontana J, Burroughs M, Hempstead M, Kaplan G, Adverse reactions to thalidomide in patients infected with human immunodeficiency virus. Clin Infect Dis 1997; 24: 1223-1227.

  82. Ordi J, Cortes F, Martínez N, Mauri M, De Torres I, Vilardell M. Thalidomide induces amenorrhea in patients with lupus disease. Arthritis Rheum 1998; 41: 2273-2275.




2020     |     www.medigraphic.com